论文部分内容阅读
目的观察西妥昔单抗分别联合FOLFOX与FOLFIRI两种化疗方案治疗晚期直肠癌患者的临床疗效和毒副反应。方法将80例晚期直肠癌患者随机分为A、B两组，每组各40例；A组：使用西妥昔单抗联合FOLFOX化疗方案治疗，B组：使用西妥昔单抗联合FOLFIRI化疗方案治疗。治疗6周后观察比较两组患者的近期疗效、生活质量和不良反应。结果 A、B两组患者的有效率和生活质量改善率比较差异无显著性（P ＞0．05）；两组患者的肿瘤直径和厚度均较治疗前明显减小（P ＜0．05），但两组之间比较差异无显著性（P ＞0．05）；两组不良发应在腹泻、神经毒性的发生上差异有统计学意义（P ＜0．05）。结论西妥昔单抗分别联合FOLFOX与FOLFIRI两种方案治疗晚期直肠癌疗效相当，但在不良反应方面前者以神经毒性反应多见，后者以腹泻多见，总发生率两者相当。“,”[Objective] To explore the clinical efficacies and adverse reactions of cetuximab plus FOLFOX or FOLFIRI chemotherapy in the treatment of advanced colorectal cancer .[Methods] A total of 80 patients with advanced colorectal cancer patients were randomly divided into A and B groups ( n=40 each) .Group A received cetuximab plus FOLFOX regimen while group B cetuximab plus FOLFIRI chemotherapy .And their immediate outcomes ,quality of life and adverse reactions after 6 weeks were recorded and compared .[Re‐sults] There were insignificant inter‐group differences in efficiency or life quality improvement rate ( P >0 .05) .For both groups ,the diameter and thickness of tumor significantly decreased as compared with pre‐treatment ( P 0 .05) .Occurrences of diarrhea and neurotoxicity had significant inter‐group differences ( P <0 .05) .[Conclusion]Cetuximab plus FOLFOX or FOLFIRI has similar efficacies for advanced colorectal cancer .Only individual differences exist in adverse reactions .